

Sagar Lonial

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378252/publications.pdf>

Version: 2024-02-01

425
papers

44,927
citations

7069

78
h-index

2071

204
g-index

430
all docs

430
docs citations

430
times ranked

41310
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
3	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
4	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2005, 352, 2487-2498.	13.9	2,356
5	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
6	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
7	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	13.7	1,288
8	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. <i>New England Journal of Medicine</i> , 2007, 357, 2133-2142.	13.9	1,186
9	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
10	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
11	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
12	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
13	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 116, 679-686.	0.6	790
14	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1551-1560.	6.3	724
15	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
16	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
17	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4867-4874.	0.8	675
18	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012, 120, 2817-2825.	0.6	608
20	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
21	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	5.1	544
22	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	0.6	485
23	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
24	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
25	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2017, 130, 974-981.	0.6	391
26	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	0.6	347
27	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
28	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	0.6	306
29	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	1.7	300
30	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€“modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	1.2	289
31	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
32	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , 2013, 122, 2331-2337.	0.6	281
33	Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1953-1959.	0.8	273
34	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
35	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. <i>Molecular Cell</i> , 2014, 53, 534-548.	4.5	247
36	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4784-4790.	0.8	244

#	ARTICLE	IF	CITATIONS
37	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , 2007, 109, 2604-2606.	0.6	242
38	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3518-3525.	0.8	241
39	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2012, 119, 5661-5670.	0.6	235
40	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	5.1	233
41	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 1484-1496.	4.6	224
42	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	5.1	219
43	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014, 124, 1038-1046.	0.6	192
44	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	0.6	174
45	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
46	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	0.8	161
47	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2017, 1, 2105-2114.	2.5	155
48	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	0.8	148
49	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
50	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e516-e527.	2.2	140
51	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.	0.6	136
52	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
53	Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , 2001, 97, 2948-2956.	0.6	127
54	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	4.5	125

#	ARTICLE	IF	CITATIONS
55	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	0.6	121
56	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>ELOQUENT</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
57	Treatment Options for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1264-1277.	3.2	118
58	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4243-4249.	0.8	118
59	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT trial. <i>Cancer</i> , 2018, 124, 4032-4043.	2.0	118
60	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 279-289.	1.1	117
61	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.	1.2	115
62	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1820-1823.	0.6	109
63	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. <i>Cell Metabolism</i> , 2017, 25, 358-373.	7.2	109
64	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	5.8	109
65	Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. <i>Molecular Cell</i> , 2014, 55, 552-565.	4.5	107
66	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	2.3	107
67	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 310-318.	0.2	104
68	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	2.8	104
69	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , 2011, 153, 729-740.	1.2	102
70	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020, 9, 889-911.	1.0	101
71	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	2.0	100
72	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 57-67.	1.1	97
74	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. <i>Clinical Cancer Research</i> , 2010, 16, 5079-5086.	3.2	94
75	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , 2018, 34, 315-330.e7.	7.7	94
76	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell "Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	0.5	93
77	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.	1.2	91
78	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	2.8	90
79	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM2 study. <i>Cancer</i> , 2021, 127, 4198-4212.	2.0	89
80	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011, 118, 535-543.	0.6	82
81	How I treat high-risk myeloma. <i>Blood</i> , 2015, 126, 1536-1543.	0.6	77
82	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	2.2	74
83	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
84	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. <i>Molecular Cell</i> , 2016, 64, 859-874.	4.5	73
85	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of retreatment with daratumumab among refractory patients. <i>Cancer</i> , 2019, 125, 2991-3000.	2.0	73
86	PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. <i>Future Oncology</i> , 2007, 3, 639-647.	1.1	70
87	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. <i>Nucleic Acids Research</i> , 2017, 45, 2396-2407.	6.5	69
88	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 372-380.	0.2	66
89	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 97-111.	1.0	65
90	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. <i>Blood</i> , 2014, 123, 3269-3276.	0.6	64

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. <i>Clinical Pharmacokinetics</i> , 2017, 56, 915-924.	1.6	64
92	Review of peripheral neuropathy in plasma cell disorders. <i>Hematological Oncology</i> , 2008, 26, 55-65.	0.8	63
93	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1228.	5.8	62
94	The Tao of myeloma. <i>Blood</i> , 2014, 124, 1873-1879.	0.6	60
95	Academic, Foundation, and Industry Collaboration in Finding New Therapies. <i>New England Journal of Medicine</i> , 2017, 376, 1762-1769.	13.9	57
96	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.	0.8	57
97	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. <i>Blood</i> , 2005, 106, 4322-4329.	0.6	56
98	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	0.8	56
99	Clinical uses of GM-CSF, a critical appraisal and update. <i>Biologics: Targets and Therapy</i> , 2008, 2, 13.	3.0	51
100	Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 508-508.	0.6	50
101	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , 2018, 124, 2075-2085.	2.0	49
102	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	1.1	48
103	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
104	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
105	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	5.1	46
106	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. <i>Cancer</i> , 2006, 106, 2171-2180.	2.0	45
107	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
108	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45

#	ARTICLE	IF	CITATIONS
109	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021, 137, 3604-3615.	0.6	44
110	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
111	A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 4617-4630.	2.0	43
112	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 848-857.	2.0	42
113	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42
114	Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 370-376.	0.2	41
115	Safety of proteasome inhibitors for treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-17.	1.0	40
116	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 106.	2.8	40
117	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5959-5965.	3.2	39
118	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. <i>Blood Cancer Journal</i> , 2019, 9, 3.	2.8	39
119	β -6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. <i>Molecular Cell</i> , 2019, 76, 857-871.e9.	4.5	39
120	DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN \rightarrow WEE1 Signaling. <i>Clinical Cancer Research</i> , 2020, 26, 3843-3855.	3.2	38
121	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. <i>Journal of Clinical Oncology</i> , 2021, 39, 8016-8016.	0.8	38
122	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
123	Bortezomib-containing induction regimens in transplant-eligible myeloma patients. <i>Cancer</i> , 2013, 119, 4119-4128.	2.0	36
124	Integration of Novel Agents into the Care of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5443-5452.	3.2	36
125	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019, 125, 416-423.	2.0	36
126	Relapsed Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 303-309.	0.9	35

#	ARTICLE	IF	CITATIONS
127	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. <i>Journal of Oncology Practice</i> , 2018, 14, 414-422.	2.5	35
128	High-risk Multiple Myeloma: Definition and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S80-S87.	0.2	34
129	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. , 2020, 8, e001302.		34
130	Subcutaneous Versus Intravenous Bortezomib. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1136-1142.	0.9	33
131	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
132	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. <i>Oncotarget</i> , 2016, 7, 59727-59741.	0.8	33
133	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. <i>Cancer</i> , 2010, 116, 3143-3151.	2.0	32
134	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1731-1740.	1.4	32
135	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021, 11, 103.	2.8	32
136	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2009, 145, 681-708.	1.2	31
137	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	0.8	31
138	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 305-305.	0.6	30
139	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 852-857.	2.0	29
140	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2018, 124, 4342-4349.	2.0	29
141	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. <i>Journal of Biological Chemistry</i> , 2017, 292, 10142-10152.	1.6	28
142	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , 2019, 129, 2431-2445.	3.9	28
143	Racial Differences in the Incidence and Outcomes for Patients with Hematological Malignancies. <i>Current Problems in Cancer</i> , 2007, 31, 182-201.	1.0	26
144	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	3.1	25

#	ARTICLE	IF	CITATIONS
145	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 406-406.	0.6	25
146	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	1.3	24
147	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	1.0	24
148	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	1.6	24
149	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8536-8536.	0.8	24
150	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	2.6	24
151	Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. <i>Cancer Letters</i> , 2018, 435, 44-54.	3.2	23
152	Is there still a role for stem cell transplantation in multiple myeloma?. <i>Cancer</i> , 2019, 125, 2534-2543.	2.0	23
153	Maintenance Therapy in Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 507-513.	1.4	22
154	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. <i>Journal of Clinical Investigation</i> , 2019, 129, 4110-4123.	3.9	22
155	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.	0.6	22
156	Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 293-311.	1.4	20
157	Integrated Analysis of Whole-Genome Paired-End and Mate-Pair Sequencing Data for Identifying Genomic Structural Variations in Multiple Myeloma. <i>Cancer Informatics</i> , 2014, 13s2, CIN.S13783.	0.9	20
158	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4421-4430.	0.8	20
159	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA trial. <i>British Journal of Haematology</i> , 2018, 181, 628-636.	1.2	20
160	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.. <i>Blood</i> , 2008, 112, 1742-1742.	0.6	20
161	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) Tj ETQq1 0.0.7843 124rgBT /Ov		
162	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007, 47, 629-635.	0.8	19

#	ARTICLE	IF	CITATIONS
163	Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 460-467.	2.0	19
164	HLA polymorphism and risk of multiple myeloma. <i>Leukemia</i> , 2016, 30, 2260-2264.	3.3	19
165	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 759-759.	0.6	19
166	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , 2016, 7, 27753-27763.	0.8	19
167	Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting. <i>Life Science Alliance</i> , 2022, 5, e202101285.	1.3	19
168	SOHO State of the Art Updates and Next Questions: T-Cellâ€“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€“Modified T Cells and Bispecific T-Cellâ€“Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.2	18
169	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , 2019, 9, 756-777.	7.7	18
170	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	1.2	18
171	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , 2007, 110, 1165-1165.	0.6	18
172	Presentation and risk stratification â€“ improving prognosis for patients with multiple myeloma. <i>Cancer Treatment Reviews</i> , 2010, 36, S12-S17.	3.4	17
173	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016, 17, 769-777.	1.5	17
174	Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib. <i>Blood</i> , 2008, 112, 870-870.	0.6	17
175	Interim Analysis of the Mmrf Compass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression. <i>Blood</i> , 2014, 124, 722-722.	0.6	17
176	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. <i>Blood</i> , 2015, 126, 4222-4222.	0.6	17
177	Phase II study of daratumumab (DARA) monotherapy in patients with â‰¥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8512-LBA8512.	0.8	17
178	Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. <i>Cell</i> , 2022, 185, 1974-1985.e12.	13.5	17
179	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	1.2	16
180	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 332-344.	0.2	16

#	ARTICLE	IF	CITATIONS
181	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011, 118, 811-811.	0.6	16
182	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	0.6	16
183	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	2.5	16
184	CD86 regulates myeloma cell survival. <i>Blood Advances</i> , 2017, 1, 2307-2319.	2.5	15
185	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	2.8	15
186	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	3.2	15
187	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology</i> , 2021, 8, e794-e807.	2.2	15
188	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	2.6	15
189	ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8508-8508.	0.8	15
190	Breakthroughs in the Management of Multiple Myeloma. <i>Drugs</i> , 2003, 63, 1621-1636.	4.9	14
191	Eliminating the complete response penalty from myeloma response assessment. <i>Blood</i> , 2008, 111, 3297-3298.	0.6	14
192	Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S71-S77.	0.2	14
193	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4787.	1.7	14
194	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low I \pm -1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. <i>Blood</i> , 2013, 122, 285-285.	0.6	14
195	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. <i>Blood</i> , 2014, 124, 32-32.	0.6	14
196	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. <i>Biologics: Targets and Therapy</i> , 2013, 7, 13.	3.0	13
197	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011, 118, 1876-1876.	0.6	13
198	Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). <i>Blood</i> , 2011, 118, 814-814.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Rocilinosat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. <i>Blood</i> , 2012, 120, 4061-4061.	0.6	13
200	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 302-302.	0.6	13
201	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8519-8519.	0.8	13
202	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.2	13
203	Regulation of alloimmune responses by dendritic cell subsets. <i>Experimental Hematology</i> , 2008, 36, 1309-1317.	0.2	12
204	Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 657-663.	0.2	12
205	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
206	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e431-e441.	1.8	12
207	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. <i>Molecular Cell</i> , 2018, 69, 923-937.e8.	4.5	12
208	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 985-985.	0.6	12
209	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1.. <i>Blood</i> , 2011, 118, 3976-3976.	0.6	12
210	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	0.6	12
211	Phase 1B Results of Ricolinosat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	0.6	12
212	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	0.6	12
213	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8542-8542.	0.8	12
214	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2155-2162.	0.6	11
215	Multiple Myeloma Presenting with Advanced Renal Failure: A Case Report and New Treatment Options. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 52-54.	1.4	11
216	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. <i>Nucleic Acids Research</i> , 2016, 44, e69-e69.	6.5	11

#	ARTICLE	IF	CITATIONS
217	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , 2017, 10, 933-939.	1.0	11
218	Daratumumab With Cetrelimab, an Anti-“PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 46-54.e4.	0.2	11
219	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 47-48.	0.6	11
220	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. <i>Blood</i> , 2009, 114, 430-430.	0.6	11
221	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	0.6	11
222	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
223	Signal Transduction and Myeloma: New Targets, New Hope. <i>Cancer Biology and Therapy</i> , 2003, 2, 310-319.	1.5	10
224	Myeloma Is Not a Single Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 287-292.	2.5	10
225	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1291-1301.	1.4	10
226	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. <i>Future Oncology</i> , 2018, 14, 3111-3121.	1.1	10
227	Smoldering Myeloma and the Art of War. <i>Journal of Clinical Oncology</i> , 2020, 38, 2363-2365.	0.8	10
228	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.	4.5	10
229	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. <i>Blood</i> , 2007, 110, 187-187.	0.6	10
230	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015, 126, 1827-1827.	0.6	10
231	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8040-8040.	0.8	10
232	Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 310-313.	0.9	9
233	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	3.2	9
234	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 301-301.	0.6	9

#	ARTICLE	IF	CITATIONS
235	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	0.6	9
236	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8510-8510.	0.8	9
237	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e431-e441.	1.8	9
238	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. <i>Journal of Oncology Practice</i> , 2018, 14, 561-564.	2.5	8
239	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	1.4	8
240	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , 2020, 37, 1464-1478.	1.3	8
241	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 303-303.	0.6	8
242	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. <i>Blood</i> , 2013, 122, 3135-3135.	0.6	8
243	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8541-8541.	0.8	8
244	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 19-28.	2.3	7
245	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
246	Monoclonal Antibodies for the Treatment of Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 3-6.	1.0	7
247	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. <i>PLoS ONE</i> , 2019, 14, e0206309.	1.1	7
248	Downregulation of PA28 $\hat{\pm}$ induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	2.8	7
249	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021, 96, E68-E71.	2.0	7
250	What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2423-2425.	0.8	7
251	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 169-180.	0.8	7
252	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009, 114, 132-132.	0.6	7

#	ARTICLE	IF	CITATIONS
253	Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.. Blood, 2009, 114, 2879-2879.	0.6	7
254	Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.. Blood, 2009, 114, 3890-3890.	0.6	7
255	Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. Blood, 2015, 126, 29-29.	0.6	7
256	Antibody treatment in multiple myeloma. Clinical Advances in Hematology and Oncology, 2021, 19, 166-174.	0.3	7
257	The Future of Drug Development and Therapy in Myeloma. Seminars in Oncology, 2013, 40, 652-658.	0.8	6
258	Plerixafor in combination with granulocyteâ€œcolonyâ€œstimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion, 2015, 55, 2351-2357.	0.8	6
259	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British Journal of Cancer, 2020, 123, 1228-1234.	2.9	6
260	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	1.0	6
261	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 26-27.	0.6	6
262	A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3706-3706.	0.6	6
263	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. Blood, 2009, 114, 1689-1689.	0.6	6
264	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood, 2010, 116, 1954-1954.	0.6	6
265	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. Blood, 2010, 116, 986-986.	0.6	6
266	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood, 2012, 120, 1852-1852.	0.6	6
267	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. Journal of Clinical Oncology, 2013, 31, 8517-8517.	0.8	6
268	Changes in the pattern of TCR VÎ² repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. British Journal of Haematology, 2001, 113, 224-230.	1.2	5
269	Novel Treatment Approaches for Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 281-288.	1.4	5
270	Proteasome Inhibition: Novel Therapy for Multiple Myeloma. Oncology Research and Treatment, 2006, 29, 162-168.	0.8	5

#	ARTICLE	IF	CITATIONS
271	Multiple Myeloma: Novel Approaches for Relapsed Disease. <i>Clinical Lymphoma and Myeloma</i> , 2007, 8, S18-S23.	1.4	5
272	Treatment of relapsed and refractory myeloma. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 99-107.	1.2	5
273	Is Subcutaneous Bortezomib Ready for Prime Time?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 73-74.	1.2	5
274	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: Synergy for all the right reasons. <i>Autophagy</i> , 2011, 7, 448-449.	4.3	5
275	Sequential or combination therapy for multiple myeloma. <i>Expert Review of Hematology</i> , 2012, 5, 533-545.	1.0	5
276	Precision medicine in multiple myeloma: are we there yet?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 51-53.	0.4	5
277	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.2	5
278	Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.. <i>Blood</i> , 2009, 114, 532-532.	0.6	5
279	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 3031-3031.	0.6	5
280	ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 1860-1860.	0.6	5
281	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. <i>Blood</i> , 2011, 118, 3994-3994.	0.6	5
282	MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment. <i>Blood</i> , 2014, 124, 4730-4730.	0.6	5
283	Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response. <i>Blood</i> , 2016, 128, 4406-4406.	0.6	5
284	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18572-e18572.	0.8	5
285	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8526-8526.	0.8	5
286	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , 2011, 118, 2988-2988.	0.6	5
287	Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. <i>Lancet Haematology</i> , the, 2022, 9, e162-e165.	2.2	5
288	Supportive Therapies in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 971-979.	2.3	4

#	ARTICLE	IF	CITATIONS
289	Improving Induction Therapy in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 119-128.	1.2	4
290	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , 2013, 53, 76-84.	0.8	4
291	Novel combination approaches for myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 286-293.	0.9	4
292	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 514-518.	0.2	4
293	Emerging treatments in Castleman disease – a critical appraisal of siltuximab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 9.	3.0	4
294	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. <i>Cancer</i> , 2018, 124, 4358-4365.	2.0	4
295	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	2.0	4
296	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 701-710.	0.2	4
297	A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1959-1959.	0.6	4
298	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. <i>Blood</i> , 2011, 118, 1855-1855.	0.6	4
299	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Mveloma. <i>Blood</i> , 2014, 124, 2120-2120.	0.6	4
300	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8532-8532.	0.8	4
301	Phase II study of daratumumab (DARA) monotherapy in patients with 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8512-LBA8512.	0.8	4
302	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. <i>Oncology</i> , 2011, 25 Suppl 2, 25-31.	0.4	4
303	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 725-727.	0.6	3
304	Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e59-e63.	0.2	3
305	Relapsed and Refractory Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 861-890.	0.9	3
306	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019, 134, 1872-1872.	0.6	3

#	ARTICLE	IF	CITATIONS
307	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	0.6	3
308	Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3605-3605.	0.6	3
309	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2007, 110, 949-949.	0.6	3
310	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. <i>Blood</i> , 2008, 112, 3701-3701.	0.6	3
311	Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2865-2865.	0.6	3
312	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. <i>Blood</i> , 2010, 116, 1952-1952.	0.6	3
313	Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) â€” a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2011, 118, 504-504.	0.6	3
314	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8584-8584.	0.8	3
315	The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2935-2935.	0.6	3
316	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. <i>Blood</i> , 2021, 138, 2746-2746.	0.6	3
317	β^2 adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. <i>Haematologica</i> , 2022, 107, 2226-2231.	1.7	3
318	When â€œthe sameâ€ is really â€œdifferentâ€? <i>Blood</i> , 2006, 108, 3233-3234.	0.6	2
319	Novel treatment approaches for patients with relapsed and refractory multiple myeloma. <i>Current Treatment Options in Oncology</i> , 2006, 7, 246-257.	1.3	2
320	Down to the bitter end. <i>Blood</i> , 2014, 123, 3061-3062.	0.6	2
321	Panobinostat for the treatment of multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 229-238.	0.5	2
322	Treatment of MM: Upcoming Novel Therapies. <i>Cancer Treatment and Research</i> , 2016, 169, 195-205.	0.2	2
323	â€œI took the road less traveled, and that has made all the differenceâ€ Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2021, 127, 4133-4136.	2.0	2
324	Safety and Efficacy of Evomelaâ„¢ in Myeloma Autotransplants. <i>Blood</i> , 2018, 132, 3446-3446.	0.6	2

#	ARTICLE	IF	CITATIONS
325	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018, 132, 3294-3294.	0.6	2
326	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML. <i>Blood</i> , 2004, 104, 1814-1814.	0.6	2
327	Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phospho-PDK1 in Human Lymphoma and Leukemia Cell Lines. <i>Blood</i> , 2005, 106, 1488-1488.	0.6	2
328	Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation. <i>Blood</i> , 2007, 110, 1520-1520.	0.6	2
329	Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients. <i>Blood</i> , 2007, 110, 3612-3612.	0.6	2
330	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration. <i>Blood</i> , 2008, 112, 3332-3332.	0.6	2
331	Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ). <i>Blood</i> , 2009, 114, 1827-1827.	0.6	2
332	Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis. <i>Blood</i> , 2011, 118, 1882-1882.	0.6	2
333	The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes. <i>Blood</i> , 2012, 120, 3980-3980.	0.6	2
334	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1924-1924.	0.6	2
335	Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective. <i>Blood</i> , 2015, 126, 4254-4254.	0.6	2
336	The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8613-TPS8613.	0.8	2
337	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. <i>Blood</i> , 2010, 116, 1942-1942.	0.6	2
338	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , 2011, 118, 1875-1875.	0.6	2
339	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. <i>Blood</i> , 2018, 132, 951-951.	0.6	2
340	Practical Considerations for Multiple Myeloma: An Overview of Recent Data and Current Options. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S144-S148.	1.4	1
341	Future directions in immunomodulatory therapy. <i>Medical Oncology</i> , 2010, 27, 62-66.	1.2	1
342	Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin. <i>Experimental Hematology</i> , 2012, 40, 95-96.	0.2	1

#	ARTICLE	IF	CITATIONS
343	Death by a thousand cuts: the slow demise of chemotherapy. <i>Cancer</i> , 2016, 122, 1971-1973.	2.0	1
344	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	0.6	1
345	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	0.6	1
346	Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 22-23.	0.6	1
347	Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.. <i>Blood</i> , 2005, 106, 1568-1568.	0.6	1
348	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT).. <i>Blood</i> , 2006, 108, 3224-3224.	0.6	1
349	FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation. <i>Blood</i> , 2008, 112, 3722-3722.	0.6	1
350	Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.. <i>Blood</i> , 2009, 114, 1845-1845.	0.6	1
351	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 1937-1937.	0.6	1
352	Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. <i>Blood</i> , 2011, 118, 3959-3959.	0.6	1
353	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. <i>Blood</i> , 2011, 118, 3968-3968.	0.6	1
354	Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT). <i>Blood</i> , 2011, 118, 824-824.	0.6	1
355	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012, 120, 4079-4079.	0.6	1
356	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8540-8540.	0.8	1
357	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8588-8588.	0.8	1
358	Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8609-8609.	0.8	1
359	Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8050-8050.	0.8	1
360	Maintenance Therapy in Multiple Myeloma. , 2008, , 91-98.		1

#	ARTICLE	IF	CITATIONS
361	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. Blood, 2009, 114, 3888-3888.	0.6	1
362	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. Blood, 2009, 114, 53-53.	0.6	1
363	Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.. Blood, 2009, 114, 3879-3879.	0.6	1
364	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. Blood, 2010, 116, 1963-1963.	0.6	1
365	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. Blood, 2011, 118, 3950-3950.	0.6	1
366	Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmf Commpass Analysis. Blood, 2019, 134, 1805-1805.	0.6	1
367	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. Blood, 2021, 138, 2733-2733.	0.6	1
368	Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy, 2022, 42, 233-240.	1.2	1
369	MAINTENANCE THERAPY IN MULTIPLE MYELOMA. , 0, , 37-45.		0
370	The White House crusade against â€¦ MGUS?. Blood, 2010, 116, 1020-1021.	0.6	0
371	Putting the E (evidence) in a new Era for myeloma. Leukemia and Lymphoma, 2011, 52, 349-350.	0.6	0
372	Treatment of emergent peripheral neuropathy in plasma cell disorders. , 0, , 245-254.		0
373	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2013, , 41.	1.2	0
374	Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. Cancer, 2019, 125, 2322-2324.	2.0	0
375	We need CD38 STAT-JAK. Blood, 2020, 136, 2246-2248.	0.6	0
376	Message from the Chairmen. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S1.	0.2	0
377	Reply to N. Biran et al. Journal of Clinical Oncology, 2020, 38, 1368-1369.	0.8	0
378	Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation.. Blood, 2004, 104, 3073-3073.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. Blood, 2004, 104, 3159-3159.	0.6	0
380	Patient Characteristics in CD 20+ and CD 20 ⁺ Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. Blood, 2005, 106, 4523-4523.	0.6	0
381	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. Blood, 2005, 106, 4634-4634.	0.6	0
382	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. Blood, 2005, 106, 2016-2016.	0.6	0
383	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. Blood, 2006, 108, 2889-2889.	0.6	0
384	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. Blood, 2006, 108, 1960-1960.	0.6	0
385	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2006, 108, 3065-3065.	0.6	0
386	p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.. Blood, 2007, 110, 253-253.	0.6	0
387	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. Blood, 2007, 110, 1912-1912.	0.6	0
388	Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.. Blood, 2007, 110, 2920-2920.	0.6	0
389	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. Blood, 2008, 112, 3644-3644.	0.6	0
390	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. Blood, 2008, 112, 1183-1183.	0.6	0
391	The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma.. Blood, 2009, 114, 1408-1408.	0.6	0
392	A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 3851-3851.	0.6	0
393	A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. Blood, 2009, 114, 4230-4230.	0.6	0
394	The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma. , 2011, , 69-77.		0
395	High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM). Blood, 2010, 116, 1355-1355.	0.6	0
396	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. Blood, 2010, 116, 3142-3142.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	0.6	0
416	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2021, 138, 1616-1616.	0.6	0
417	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	0.6	0
418	Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities. Blood, 2021, 138, 4958-4958.	0.6	0
419	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. Blood, 2021, 138, 1611-1611.	0.6	0
420	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5	0.6	0
421	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. Blood, 2020, 136, 20-21.	0.6	0
422	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. Blood, 2020, 136, 31-32.	0.6	0
423	Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. Blood, 2020, 136, 50-51.	0.6	0
424	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
425	Frontline regimens for multiple myeloma patients. Clinical Advances in Hematology and Oncology, 2010, 8, 331-2.	0.3	0